Are there any reported cases of lurbinectedin harming infants?

What the data show about lurbinectedin and infants

Lurbinectedin does not have published reports of direct harm to infants once they are born. The compound remains classified as pregnancy category D by the FDA because animal studies showed fetal harm, but no cases of live infants harmed by maternal exposure have been documented publicly.

Why manufacturers advise against pregnancy

Animal reproduction studies consistently showed embryo-fetal toxicity in rats and rabbits. Those findings prompted the package insert to recommend effective contraception during treatment and for six months afterward for women capable of childbearing.

What happens if a woman becomes pregnant during treatment

No clinical trial or real-world registry has published outcomes for infants born to women who received lurbinectedin during pregnancy. The absence of published cases limits any risk assessment beyond the animal data. Regulators therefore treat the drug as a potential risk rather than a proven danger to born infants.

How lurbinectedin works and its target population

Lurbinectedin binds DNA minor grooves and inhibits transcription. It is approved for previously treated metastatic small-cell lung cancer in adults. The drug is not indicated for use in children or infants, and pediatric trials have not been completed.

Can lurbinectedin pass into breast milk

No studies have measured lurbinectedin in human breast milk. Based on its large molecular weight and lipophilic properties, experts expect some excretion into milk. Drug manufacturers therefore recommend avoiding breastfeeding during treatment and for two weeks after the last dose.

Are there alternatives that avoid pregnancy concerns

Topotecan and irinotecan remain available for the same indication. Both drugs share similar pregnancy warnings, but they have longer clinical histories and published case reports that help clinicians assess risk.